Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Gains from Investment Securities (2020 - 2025)

Celularity (CELU) has disclosed Gains from Investment Securities for 6 consecutive years, with $4.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities rose 396.11% to $4.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.5 million, a 160.95% increase, with the full-year FY2024 number at -$398000.0, up 93.54% from a year prior.
  • Gains from Investment Securities was $4.3 million for Q3 2025 at Celularity, up from $14000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $104.4 million in Q3 2023 to a low of -$104.4 million in Q2 2023.
  • A 5-year average of -$1.0 million and a median of $14000.0 in 2025 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: plummeted 62788.06% in 2021, then skyrocketed 16645.28% in 2024.
  • Celularity's Gains from Investment Securities stood at -$41.2 million in 2021, then soared by 278.77% to $73.6 million in 2022, then plummeted by 108.5% to -$6.3 million in 2023, then surged by 86.75% to -$828000.0 in 2024, then soared by 614.98% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for CELU's Gains from Investment Securities are $4.3 million (Q3 2025), $14000.0 (Q2 2025), and $98000.0 (Q1 2025).